Metabolic syndrome in dermatology: Treatment and Management for Dermatologists

Engın, Burhan; Özkoca, Defne; Kutlubay, Zekayi; Serdaroğlu, Server

doi:10.1111/dth.12812

Cited by 13 publications

(16 citation statements)

References 14 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following patients were excluded from the study: those with signs of hyperandrogenism such as polycystic ovaries, androgenic alopecia, or hirsutism 8 ; smokers 9 ; subjects with diseases that affect IGF‐1 levels such as diabetes, 10 metabolic syndrome, 11 Laron syndrome, and acromegaly 12 ; underweight and overweight subjects, pregnancy, 12 conditions that affect liver 13 or thyroid 16 function, high levels of stress; celiac disease and inflammatory bowel diseases 17 ; patients on hormonal therapy, or taking corticosteroid, 18 lithium, 19 growth hormone, 20 metformin, 21 vitamin B12, 22 whey proteins, 23 and estrogenic‐progestogens 24 …”

Section: Methodsmentioning

confidence: 99%

Do acne treatments affect insulin‐like growth factor‐1 serum levels? A clinical and laboratory study on patients with acne vulgaris

Rodighiero

Bertolani

Saleri

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Acne is a chronic inflammatory disease affecting sebaceous gland follicles. Lately, acne has considered an insulin‐like growth factor‐1 (IGF‐1) mediated disease. Recent research demonstrated that IGF‐1 levels decrease after 3 months of isotretinoin. The purpose of our study is evaluating the influence of acne treatments on IGF‐1 serum levels. Forty‐six subjects with acne vulgaris aged 14 to 30 years were subdivided into three groups according to their severity of acne and treated following the European Dermatology Forum guidelines. IGF‐1 was measured in patients before and after the treatment and then compared to the IGF‐1 of a healthy population of the same age. IGF‐1 resulted higher in patients than in controls but there was not a statistically significant variation after treatment. To the best of our knowledge, this is the first study evaluating the influence of topical and systemic acne treatment on IGF‐1 serum levels. In contrast with the literature, our results suggest that common therapies for acne are not able to significantly modify IGF‐1 serum levels.

show abstract

Section: Methodsmentioning

confidence: 99%

Do acne treatments affect insulin‐like growth factor‐1 serum levels? A clinical and laboratory study on patients with acne vulgaris

Rodighiero

Bertolani

Saleri

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Chronic inflammatory diseases have an important place in dermatology and can cause metabolic complications 2 . IL‐2, 4, 6, 10, and TNF‐a cytokines secretion by Th1 involved in LP pathogenesis play a causative role in MS 1 .…”

Section: Introductionmentioning

confidence: 99%

“…Abdominal adipose tissue, the key factor of MS, is an important source of these proinflammatory cytokines and adipokines 3 . Metabolic syndrome is associated with abdominal obesity, dyslipidemia, glucose intolerance, or diabetes mellitus, and hypertension 2‐4 . Several different definitions of MS exist, causing major confusion as to whether they identify the same persons or symbolize a surrogate of risk factors.…”

Section: Introductionmentioning

confidence: 99%

The relationship between lichen planus and metabolic syndrome

Daye

Temiz

Işık

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objective Lichen planus (LP) is an idiopathic, chronic inflammatory disease. Chronic inflammatory diseases can cause metabolic complications. In the literature, data related to the relationship between lichen planus and metabolic syndrome (MS) are limited. We aimed to evaluate the relationship between MS and lichen planus with disease activity. Methods The patients diagnosed with lichen planus at the dermatology outpatient clinic between January 2018 and January 2020 were retrospectively analyzed. 98 lichen planus cases, age‐ and sex‐matched 99 controls, 197 cases in total were included in the study. Results Of the 98 lichen planus cases included in the study, 60 (61%) were women. The mean age of the patients was 49.3 ± 14.4, and the average disease duration was 33.5 ± 31.4 months. 55 (55%) of the patients in the control group were female, and the mean age of the control group was 50 ± 13.2. The body mass index of LP cases was 29.5 ± 5.8, in the control group was 25.8 ± 3.7. Metabolic syndrome was found in 47 (48%) of 98 cases with lichen planus and 32.3% in the control group. MS in the lichen planus group was significantly higher than the control group (P = .025). Metabolic syndrome was detected in the oral lichen planus at the rate of 60% (12 cases). Although the incidence of MS was more common in the oral lichen planus, it was not statistically significant (P = .29). While no significant relationship was found between oral disease severity and metabolic syndrome (P = .19), a significant correlation was found between cutaneous disease severity and metabolic syndrome (P = .023). Discussion The risk of mucosal malignancy that can occur when following LP cases has been known for a long time. According to our results, caution should be taken in terms of metabolic complications in the follow‐up of LP cases, especially oral LP cases.

show abstract

“…16 In addition, the relationship between metabolic syndrome, cardiovascular diseases and HS has been mentioned in recent years. 1,17,18 The most common psychiatric comorbidities in patients with HS were reported as anxiety and depression. 19 Obesity was detected in 9 of our patients.…”

Section: Severity Of Hsmentioning

confidence: 99%